Fig. 2

Effect of sorafenib and/or GdCl3 blockage on angiogenesis in DMN-induced liver fibrosis in vivo. a vWF immunohistochemistry (magnification X400, n = 4). b Levels of mRNAs encoded by genes related to angiogenesis (n = 6). c the Expression of CD31, VEGF, Ang1, VCAM1 was analyzed using western blot (n = 6). Control, vehicle alone; 4 W, DMN for 4 weeks; S, DMN for 4 weeks plus sorafenib for 2 weeks; G, DMN for 4 weeks plus GdCl3 for 2 weeks; S + G, DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks. The negative control consisted of samples from DMN-treated animals in the absence of primary antibody. All results reported as mean ± S.D. *p < 0.05; **p < 0.01 vs 4 W